Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Medis Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (1052)
ARTG (149)
Cancellation or suspension (26)
Listed medicine compliance report (5)
Prescription medicine registration (2)

Date

2024 (866)
2023 (3)
2022 (29)
2021 (106)
2020 (31)
2019 (6)
2018 (6)
2017 (47)
2016 (5)
2015 (29)
2014 (29)
2013 (29)
2012 (23)
2011 (12)
2010 (3)
2009 (8)
2008 (1)
1993 (1)

Results for "[search-keyword]"

Search

Sponsor content

1234 result(s) found, displaying 561 to 570

EZETIMIBE/SIMVASTATIN-MEDIS 10/10 ezetimibe 10 mg and simvastatin 10 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
EZETIMIBE/SIMVASTATIN-AS 10/80 ezetimibe 10 mg and simvastatin 80 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ANIDULAFUNGIN ISL anidulafungin 100 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ANIDULAFUNGIN ZP anidulafungin 100 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ANIDULAFUNGIN GA anidulafungin 100 mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ATORVASTATIN ASCENT atorvastatin (as calcium) 10 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ATORVASTATIN-AS atorvastatin (as calcium) 40 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
ATORVASTATIN ASCENT atorvastatin (as calcium) 40 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
LIPVASTOL atorvastatin (as calcium) 20 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd
LIPVASTOL atorvastatin (as calcium) 40 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

7 June 2024

Cancellation by sponsor

Requested by Medis Pharma Pty Ltd

Pages

First page
Previous page
…
Page 53
Page 54
Page 55
Page 56
Current page 57
Page 58
Page 59
Page 60
Page 61
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.